PHARMACEUTICAL DOSAGE FORM FOR TREATMENT OF BPH USING DRUG DELIVERY SYSTEM

PURPOSE: A therapeutic agent for benign prostatic hyperplasia using a drug delivery system is provided to continuously release drug in a gastrointestinal tract. CONSTITUTION: A therapeutic agent for benign prostatic hyperplasia using a drug delivery system contains a continuous phase of hydrophobic...

Full description

Saved in:
Bibliographic Details
Main Authors CHOI, JAE SEUNG, JUNG, JAE HON, NAM, KYOUNG TAE
Format Patent
LanguageEnglish
Korean
Published 16.03.2011
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PURPOSE: A therapeutic agent for benign prostatic hyperplasia using a drug delivery system is provided to continuously release drug in a gastrointestinal tract. CONSTITUTION: A therapeutic agent for benign prostatic hyperplasia using a drug delivery system contains a continuous phase of hydrophobic polymer-coated pellet and a continuous phase containing hydrochloric acid alfuzosin and hydrophilic polymers. The hydrophobic polymer is cellulose derivative, polyvinyl acetate, or methacrylic acid-methyl ester copolymer. The hydrophilic polymers are polyethylene oxide.
Bibliography:Application Number: KR20090085613